LT3184523T - N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui - Google Patents

N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui

Info

Publication number: LT3184523T
Authority: LT; Lithuania
Prior art keywords: methyl; acell; syste; dihydropyridin; morpholinomethyl
Prior art date: 2012-04-13

Application number

LTEP16191716.6T

Other languages

English (en)

Inventor

Kevin Wayne Kuntz

Kuan-Chun Huang

Hyeong Wook Choi

Kristen SANDERS

Steven Mathieu

Arani CHANDA

Frank Fang

Original Assignee

Epizyme Inc

Eisai R&D Management Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-13

Filing date

2013-04-11

Publication date

2020-02-10

2013-04-11 Application filed by Epizyme Inc, Eisai R&D Management Co., Ltd. filed Critical Epizyme Inc

2020-02-10 Publication of LT3184523T publication Critical patent/LT3184523T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Hydrogenated Pyridines (AREA)
Pyridine Compounds (AREA)

LTEP16191716.6T 2012-04-13 2013-04-11 N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui LT3184523T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261624215P	2012-04-13	2012-04-13

Publications (1)

Publication Number	Publication Date
LT3184523T true LT3184523T (lt)	2020-02-10

Family

ID=49328166

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP16191716.6T LT3184523T (lt)	2012-04-13	2013-04-11	N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui
LTEP13774979.2T LT2836491T (lt)	2012-04-13	2013-04-11	Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTEP13774979.2T LT2836491T (lt)	2012-04-13	2013-04-11	Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma

Country Status (25)

Country	Link
US (6)	US9394283B2 (lt)
EP (4)	EP4190777A1 (lt)
JP (3)	JP6255382B2 (lt)
KR (3)	KR20220123339A (lt)
CN (2)	CN108358899B (lt)
AU (2)	AU2013245878B2 (lt)
BR (1)	BR112014025508B1 (lt)
CA (1)	CA2870005C (lt)
CY (2)	CY1119383T1 (lt)
DK (3)	DK2836491T3 (lt)
ES (3)	ES2617379T3 (lt)
HR (2)	HRP20170295T1 (lt)
HU (3)	HUE031976T2 (lt)
IL (4)	IL282732B2 (lt)
IN (1)	IN2014DN09068A (lt)
LT (2)	LT3184523T (lt)
MX (1)	MX362339B (lt)
NZ (1)	NZ700761A (lt)
PL (3)	PL3184523T3 (lt)
PT (3)	PT3184523T (lt)
RS (2)	RS59392B1 (lt)
RU (1)	RU2658911C2 (lt)
SG (3)	SG11201406468YA (lt)
SI (2)	SI3184523T1 (lt)
WO (1)	WO2013155317A1 (lt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3438B1 (ar)	2011-04-13	2019-10-20	Epizyme Inc	مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9051269B2 (en)	2011-11-18	2015-06-09	Constellation Pharmaceuticals, Inc.	Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en)	2012-02-10	2015-07-21	Constellation—Pharmaceuticals, Inc.	Modulators of methyl modifying enzymes, compositions and uses thereof
KR20230004871A (ko)	2012-04-13	2023-01-06	에피자임, 인코포레이티드	암 치료용 병용 요법
SG11201406468YA (en) *	2012-04-13	2015-01-29	Epizyme Inc	Salt form of a human hi stone methyltransf erase ezh2 inhibitor
WO2013173441A2 (en)	2012-05-16	2013-11-21	Glaxosmithkline Llc	Enhancer of zeste homolog 2 inhibitors
JP6351182B2 (ja)	2012-10-15	2018-07-04	エピザイム，インコーポレイティド	ガンの治療方法
AU2013331380B2 (en) *	2012-10-15	2018-03-22	Epizyme, Inc.	Substituted benzene compounds
US9745305B2 (en)	2013-03-15	2017-08-29	Constellation Pharmaceuticals, Inc.	Modulators of methyl modifying enzymes, compositions and uses thereof
CA2910873A1 (en)	2013-04-30	2014-11-06	Glaxosmithkline Intellectual Property (No.2) Limited	Enhancer of zeste homolog 2 inhibitors
CA2917463A1 (en)	2013-07-10	2015-01-15	Glaxosmithkline Intellectual Property (No.2) Limited	Enhancer of zeste homolog 2 inhibitors
EP3033334A1 (en)	2013-08-15	2016-06-22	Constellation Pharmaceuticals, Inc.	Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
PE20161273A1 (es)	2013-10-16	2016-12-18	Epizyme Inc	Forma salina de hidrocloruro para la inhibicion de ezh2
JP2016533364A (ja) *	2013-10-18	2016-10-27	エピザイム，インコーポレイティド	癌を処置する方法
US9738630B2 (en)	2013-11-19	2017-08-22	Bristol-Myers Squibb Company	Inhibitors of lysine methyl transferase
KR20210117347A (ko)	2013-12-06	2021-09-28	에피자임, 인코포레이티드	암 치료를 위한 병용 요법
IL309539A (en)	2014-06-17	2024-02-01	Epizyme Inc	EZH2 inhibitors for the treatment of lymphoma
WO2015195862A1 (en)	2014-06-20	2015-12-23	Constellation Pharmaceuticals, Inc.	Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4s5-e]azepin-4-yl)acetamide
CN112168967A (zh)	2014-10-16	2021-01-05	Epizyme股份有限公司	治疗癌症的方法
EP3220916B1 (en) *	2014-11-17	2023-04-19	Epizyme, Inc.	Method for treating cancer with n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl) amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide
TW201636344A (zh)	2014-12-05	2016-10-16	美國禮來大藥廠	Ｅｚｈ２抑制劑
AU2016252546A1 (en)	2015-04-20	2017-11-02	Epizyme, Inc.	Combination therapy for treating cancer
MX2017015938A (es)	2015-06-10	2018-11-09	Epizyme Inc	Inhibidores de ezh2 para el tratar linfomas.
CN108025191A (zh)	2015-08-24	2018-05-11	Epizyme股份有限公司	治疗癌症的方法
TW201718598A (zh)	2015-08-27	2017-06-01	美國禮來大藥廠	Ｅｚｈ２抑制劑
WO2017040190A1 (en)	2015-08-28	2017-03-09	Constellation Pharmaceuticals, Inc.	Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
JP2019503391A (ja)	2016-01-29	2019-02-07	エピザイム，インコーポレイティド	癌を処置するための併用療法
CA3025933A1 (en)	2016-06-01	2017-12-07	Epizyme, Inc.	Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en)	2016-06-17	2020-02-26	Epizyme Inc	EZH2 INHIBITORS TO TREAT CANCER
EP3529242A1 (en)	2016-10-19	2019-08-28	Constellation Pharmaceuticals, Inc.	Synthesis of inhibitors of ezh2
US11214561B2 (en) *	2017-01-25	2022-01-04	Ancureall Pharmaceutical (Shanghai) Co., Ltd.	Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof
WO2018183885A1 (en)	2017-03-31	2018-10-04	Epizyme, Inc.	Combination therapy for treating cancer
CN110944628A (zh)	2017-06-02	2020-03-31	Epizyme股份有限公司	使用ezh2抑制剂治疗癌症
CA3074720A1 (en)	2017-09-05	2019-03-14	Epizyme, Inc.	Combination therapy for treating cancer
CA3104209A1 (en)	2018-07-09	2020-01-16	Fondation Asile Des Aveugles	Inhibition of prc2 subunits to treat eye disorders
WO2021035194A1 (en)	2019-08-22	2021-02-25	Juno Therapeutics, Inc.	Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN115175904A (zh) *	2019-12-20	2022-10-11	Epizyme股份有限公司	Ezh2抑制剂的结晶氢溴酸盐、其制备和用于治疗癌症的药物组合物
WO2022208552A1 (en) *	2021-03-31	2022-10-06	Msn Laboratories Private Limited, R&D Center	Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0733729A (ja)	1993-07-26	1995-02-03	Kirin Brewery Co Ltd	Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
EP0686625B1 (en)	1993-12-27	1999-05-26	Eisai Co., Ltd.	Anthranilic acid derivative
DE19516776A1 (de)	1995-05-10	1996-11-14	Boehringer Ingelheim Int	Chromatin-Regulatorgene
US5741819A (en)	1995-06-07	1998-04-21	3-Dimensional Pharmaceuticals, Inc.	Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja)	1995-12-18	2007-04-18	杏林製薬株式会社	Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
JP2002525352A (ja)	1998-09-30	2002-08-13	ザ、プロクター、エンド、ギャンブル、カンパニー	２−置換ケトアミド
UA71587C2 (uk)	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en)	2000-11-06	2004-03-23	Bristol-Myers Squibb Pharma Company	Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
WO2002053543A1 (fr)	2000-12-28	2002-07-11	Shionogi & Co., Ltd.	Derive de pyridone ayant une affinite pour le recepteur cannabinoide de type 2
US7700293B2 (en)	2001-08-02	2010-04-20	The Regents Of The University Of Michigan	Expression profile of prostate cancer
TW200303304A (en) *	2002-02-18	2003-09-01	Astrazeneca Ab	Chemical compounds
EP1477186B1 (en)	2002-02-19	2009-11-11	Shionogi & Co., Ltd.	Antipruritics
TW200306155A (en)	2002-03-19	2003-11-16	Du Pont	Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en)	2003-06-13	2008-10-28	The University Of North Carolina At Chapel Hill	DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
RU2006138036A (ru) *	2004-03-30	2008-05-10	Чирон Корпорейшн (Us)	Производные замещенного тиофена в качестве противораковых средств
EP1765994B1 (en)	2004-06-01	2009-11-18	The University of North Carolina at Chapel Hill	Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en)	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
ATE494548T1 (de)	2005-06-02	2011-01-15	Univ North Carolina	Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
FR2889526B1 (fr)	2005-08-04	2012-02-17	Aventis Pharma Sa	7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PE20110285A1 (es)	2005-10-19	2011-06-04	Gruenenthal Chemie	Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1
EP1951672B1 (en)	2005-10-21	2011-05-25	Merck Sharp & Dohme Corp.	Potassium channel inhibitors
US20090203057A1 (en)	2005-10-28	2009-08-13	Yi Zhang	Protein demethylases comprising a jmjc domain
KR20080080173A (ko)	2005-12-14	2008-09-02	브리스톨-마이어스 스큅 컴퍼니	세린 프로테아제 억제제로서 유용한 6-원 헤테로사이클
CA2623271A1 (en)	2006-01-20	2007-08-02	The University Of North Carolina At Chapel Hill	Interaction between dot1l polypeptide and calm-af10 fusion protein as a therapeutic target for leukemia
KR20080110905A (ko)	2006-05-15	2008-12-19	아이알엠 엘엘씨	테레프탈라메이트 화합물 및 조성물, 및 ｈｉｖ 인테그라제억제제로서의 그들의 용도
WO2007136592A2 (en)	2006-05-18	2007-11-29	Amphora Discovery Corporation	2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
WO2008108825A2 (en)	2006-10-10	2008-09-12	Burnham Institute For Medical Research	Neuroprotective compositions and methods
AU2008219166B2 (en)	2007-02-16	2013-05-16	Amgen Inc.	Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
US8338437B2 (en)	2007-02-28	2012-12-25	Methylgene Inc.	Amines as small molecule inhibitors
WO2008113006A1 (en)	2007-03-14	2008-09-18	Xenon Pharmaceuticals Inc.	Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de)	2007-04-13	2008-10-16	Grünethal GmbH	Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US20090012031A1 (en)	2007-07-03	2009-01-08	The Regents Of The University Of Michigan	EZH2 Cancer Markers
DE102007047737A1 (de) *	2007-10-05	2009-04-30	Merck Patent Gmbh	Piperidin- und Piperazinderivate
JP2011502148A (ja)	2007-10-31	2011-01-20	メルク・シャープ・エンド・ドーム・コーポレイション	疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
EA019974B1 (ru)	2007-12-19	2014-07-30	Кансер Рисерч Текнолоджи Лимитед	8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ
WO2009124137A2 (en)	2008-04-01	2009-10-08	Mount Sinai School Of Medicine Of New York University	Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en)	2008-05-29	2010-05-06	Rajapakse Hemaka A	Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2335779A1 (en)	2008-08-08	2011-06-22	New York Blood Center	Small Molecule Inhibitors of Retroviral Assembly & Maturation
FR2934995B1 (fr)	2008-08-14	2010-08-27	Sanofi Aventis	Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
US20120065247A1 (en)	2009-03-27	2012-03-15	Discoverybiomed, Inc.	Modulating ires-mediated translation
US20110021362A1 (en)	2009-07-20	2011-01-27	Constellation Pharmaceuticals	Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US8329149B2 (en)	2009-12-30	2012-12-11	Avon Products, Inc.	Topical lightening composition and uses thereof
ES2534804T3 (es) *	2010-05-07	2015-04-28	Glaxosmithkline Llc	Indazoles
EA023788B1 (ru) *	2010-05-07	2016-07-29	ГЛЭКСОСМИТКЛАЙН ЭлЭлСи	Производные индола и фармацевтические композиции на их основе
US8637509B2 (en)	2010-05-07	2014-01-28	Glaxosmithkline Llc	Azaindazoles
RU2765155C2 (ru)	2010-09-10	2022-01-26	Эпизайм, Инк.	Ингибиторы ezh2 человека и способы их применения
US9175331B2 (en)	2010-09-10	2015-11-03	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en)	2010-11-19	2013-11-21	Constellation Pharmaceuticals	Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (en)	2010-12-01	2016-09-21	Glaxosmithkline LLC	Indoles
EP2646454B1 (en)	2010-12-03	2015-07-08	Epizyme, Inc.	7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (en)	2011-02-28	2012-09-07	Epizyme, Inc.	Substituted 6,5-fused bicyclic heteroaryl compounds
TWI598336B (zh)	2011-04-13	2017-09-11	雅酶股份有限公司	經取代之苯化合物
JO3438B1 (ar)	2011-04-13	2019-10-20	Epizyme Inc	مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AU2013232229B2 (en)	2012-03-12	2017-11-23	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
SG11201406468YA (en) *	2012-04-13	2015-01-29	Epizyme Inc	Salt form of a human hi stone methyltransf erase ezh2 inhibitor
KR20230004871A (ko)	2012-04-13	2023-01-06	에피자임, 인코포레이티드	암 치료용 병용 요법
WO2013173441A2 (en)	2012-05-16	2013-11-21	Glaxosmithkline Llc	Enhancer of zeste homolog 2 inhibitors
JP6351182B2 (ja)	2012-10-15	2018-07-04	エピザイム，インコーポレイティド	ガンの治療方法
PE20161273A1 (es)	2013-10-16	2016-12-18	Epizyme Inc	Forma salina de hidrocloruro para la inhibicion de ezh2

2013
- 2013-04-11 SG SG11201406468YA patent/SG11201406468YA/en unknown
- 2013-04-11 IL IL282732A patent/IL282732B2/en unknown
- 2013-04-11 SG SG10201912109QA patent/SG10201912109QA/en unknown
- 2013-04-11 PT PT16191716T patent/PT3184523T/pt unknown
- 2013-04-11 KR KR1020227029511A patent/KR20220123339A/ko not_active Application Discontinuation
- 2013-04-11 BR BR112014025508-3A patent/BR112014025508B1/pt active IP Right Grant
- 2013-04-11 PL PL16191716T patent/PL3184523T3/pl unknown
- 2013-04-11 PT PT137749792T patent/PT2836491T/pt unknown
- 2013-04-11 LT LTEP16191716.6T patent/LT3184523T/lt unknown
- 2013-04-11 CN CN201810245662.3A patent/CN108358899B/zh active Active
- 2013-04-11 AU AU2013245878A patent/AU2013245878B2/en active Active
- 2013-04-11 DK DK13774979.2T patent/DK2836491T3/en active
- 2013-04-11 SG SG10201608577RA patent/SG10201608577RA/en unknown
- 2013-04-11 NZ NZ700761A patent/NZ700761A/en unknown
- 2013-04-11 EP EP22200677.7A patent/EP4190777A1/en active Pending
- 2013-04-11 ES ES13774979.2T patent/ES2617379T3/es active Active
- 2013-04-11 HU HUE13774979A patent/HUE031976T2/en unknown
- 2013-04-11 CA CA2870005A patent/CA2870005C/en active Active
- 2013-04-11 KR KR1020207015664A patent/KR102438340B1/ko active IP Right Grant
- 2013-04-11 JP JP2015505912A patent/JP6255382B2/ja active Active
- 2013-04-11 LT LTEP13774979.2T patent/LT2836491T/lt unknown
- 2013-04-11 IN IN9068DEN2014 patent/IN2014DN09068A/en unknown
- 2013-04-11 PL PL19180479.8T patent/PL3628670T3/pl unknown
- 2013-04-11 EP EP16191716.6A patent/EP3184523B1/en active Active
- 2013-04-11 MX MX2014012380A patent/MX362339B/es active IP Right Grant
- 2013-04-11 EP EP19180479.8A patent/EP3628670B1/en active Active
- 2013-04-11 RU RU2014145544A patent/RU2658911C2/ru not_active Application Discontinuation
- 2013-04-11 SI SI201331566T patent/SI3184523T1/sl unknown
- 2013-04-11 PT PT191804798T patent/PT3628670T/pt unknown
- 2013-04-11 KR KR1020147030684A patent/KR102120883B1/ko active IP Right Grant
- 2013-04-11 PL PL13774979T patent/PL2836491T3/pl unknown
- 2013-04-11 HU HUE16191716A patent/HUE045353T2/hu unknown
- 2013-04-11 RS RSP20191175 patent/RS59392B1/sr unknown
- 2013-04-11 EP EP13774979.2A patent/EP2836491B1/en active Active
- 2013-04-11 DK DK19180479.8T patent/DK3628670T3/da active
- 2013-04-11 ES ES19180479T patent/ES2931316T3/es active Active
- 2013-04-11 IL IL296199A patent/IL296199B1/en unknown
- 2013-04-11 SI SI201330551A patent/SI2836491T1/sl unknown
- 2013-04-11 WO PCT/US2013/036193 patent/WO2013155317A1/en active Application Filing
- 2013-04-11 ES ES16191716T patent/ES2745016T3/es active Active
- 2013-04-11 RS RS20170198A patent/RS55690B1/sr unknown
- 2013-04-11 HU HUE19180479A patent/HUE060881T2/hu unknown
- 2013-04-11 DK DK16191716.6T patent/DK3184523T3/da active
- 2013-04-11 US US14/394,431 patent/US9394283B2/en active Active
- 2013-04-11 CN CN201380030902.3A patent/CN104603130B/zh active Active
2014
- 2014-10-07 IL IL235045A patent/IL235045B/en active IP Right Grant
2016
- 2016-06-30 US US15/199,522 patent/US9872862B2/en active Active
2017
- 2017-02-22 HR HRP20170295TT patent/HRP20170295T1/hr unknown
- 2017-03-06 CY CY20171100290T patent/CY1119383T1/el unknown
- 2017-10-12 JP JP2017198642A patent/JP6634058B2/ja active Active
- 2017-12-11 US US15/837,390 patent/US10245269B2/en active Active
2018
- 2018-01-09 AU AU2018200168A patent/AU2018200168B2/en active Active
- 2018-10-02 JP JP2018187463A patent/JP2018199740A/ja active Pending
2019
- 2019-02-08 US US16/270,752 patent/US10821113B2/en active Active
- 2019-04-21 IL IL266165A patent/IL266165B/en active IP Right Grant
- 2019-09-13 HR HRP20191653TT patent/HRP20191653T1/hr unknown
- 2019-09-18 CY CY20191100981T patent/CY1122883T1/el unknown
2020
- 2020-09-25 US US17/032,432 patent/US11491163B2/en active Active
2022
- 2022-09-29 US US17/936,555 patent/US20230140327A1/en active Pending

Also Published As

Publication number	Publication date
JP6634058B2 (ja)	2020-01-22
CN108358899A (zh)	2018-08-03
US20190269692A1 (en)	2019-09-05
AU2018200168B2 (en)	2019-08-29
SG10201912109QA (en)	2020-02-27
JP2015512942A (ja)	2015-04-30
US20170143729A1 (en)	2017-05-25
US10245269B2 (en)	2019-04-02
JP6255382B2 (ja)	2017-12-27
KR20200066380A (ko)	2020-06-09
ES2617379T3 (es)	2017-06-16
PT3628670T (pt)	2022-12-02
CN108358899B (zh)	2021-07-27
ES2745016T3 (es)	2020-02-27
JP2018199740A (ja)	2018-12-20
IL296199B1 (en)	2024-08-01
SG10201608577RA (en)	2016-12-29
RS59392B1 (sr)	2019-11-29
US9394283B2 (en)	2016-07-19
RS55690B1 (sr)	2017-07-31
EP2836491A1 (en)	2015-02-18
US11491163B2 (en)	2022-11-08
CY1122883T1 (el)	2022-03-24
PL2836491T3 (pl)	2017-08-31
SI2836491T1 (sl)	2017-06-30
US20150065503A1 (en)	2015-03-05
IL235045A0 (en)	2014-12-31
RU2014145544A (ru)	2016-06-10
IL266165B (en)	2021-06-30
SI3184523T1 (sl)	2020-04-30
PT3184523T (pt)	2019-09-26
IL296199A (en)	2022-11-01
IL266165A (en)	2019-06-30
HUE060881T2 (hu)	2023-04-28
KR20150002730A (ko)	2015-01-07
IL235045B (en)	2019-05-30
EP3184523B1 (en)	2019-06-19
KR102120883B1 (ko)	2020-06-09
DK3628670T3 (da)	2022-12-05
US20180243316A1 (en)	2018-08-30
HUE031976T2 (en)	2017-08-28
PL3184523T3 (pl)	2019-12-31
JP2018002742A (ja)	2018-01-11
IN2014DN09068A (lt)	2015-05-22
US10821113B2 (en)	2020-11-03
IL282732B (en)	2022-12-01
RU2658911C2 (ru)	2018-06-26
EP4190777A1 (en)	2023-06-07
KR20220123339A (ko)	2022-09-06
WO2013155317A1 (en)	2013-10-17
AU2018200168A1 (en)	2018-02-01
EP3184523A1 (en)	2017-06-28
CN104603130B (zh)	2018-04-27
US9872862B2 (en)	2018-01-23
EP3628670A1 (en)	2020-04-01
IL282732A (en)	2021-06-30
IL282732B2 (en)	2023-04-01
PL3628670T3 (pl)	2023-02-20
CY1119383T1 (el)	2018-02-14
CA2870005C (en)	2021-06-22
MX2014012380A (es)	2015-07-23
SG11201406468YA (en)	2015-01-29
AU2013245878A1 (en)	2014-10-30
NZ700761A (en)	2016-09-30
KR102438340B1 (ko)	2022-08-30
ES2931316T3 (es)	2022-12-28
BR112014025508B1 (pt)	2020-11-17
CA2870005A1 (en)	2013-10-17
HRP20191653T1 (hr)	2020-02-21
EP2836491B1 (en)	2016-12-07
HUE045353T2 (hu)	2019-12-30
CN104603130A (zh)	2015-05-06
EP3628670B1 (en)	2022-10-12
US20210137936A1 (en)	2021-05-13
LT2836491T (lt)	2017-03-27
AU2013245878B2 (en)	2017-10-12
HRP20170295T1 (hr)	2017-04-21
US20230140327A1 (en)	2023-05-04
DK3184523T3 (da)	2019-08-19
MX362339B (es)	2019-01-11
DK2836491T3 (en)	2017-03-06
PT2836491T (pt)	2017-02-08
EP2836491A4 (en)	2015-09-16

Publication	Publication Date	Title
LT3184523T (lt)	2020-02-10	N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui
PL3220916T3 (pl)	2023-08-14	Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem
SG10201901977XA (en)	2019-04-29	Hydrochloride salt form for ezh2 inhibition
IL277028A (en)	2020-10-29	A preparation containing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[5,4-b]pyridin-2-yl)pyridin-2-amine or its derivative for use in the treatment of multiple sclerosis Cells
IL275092A (en)	2020-07-30	Methods for treating Crohn's disease using an anti-IL-23 antibody
SI3097098T1 (sl)	2020-07-31	Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina
IL237369B (en)	2018-11-29	N-]2-(6-fluoro-h1-indol-3-yl)ethyl]-3-(2, 2, 3, 3- tetrafluoropropoxy) benzylamine in combination with an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
DK2696967T3 (da)	2021-08-16	Apparat til behandling af materialer i fluidiseret leje.
ZA201402907B (en)	2015-04-29	Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
GEP20186878B (en)	2018-07-10	2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
EP3806679C0 (en)	2023-08-30	CAPSULES INTENDED FOR USE IN PERSONAL VAPORIZERS
GB2556856B (en)	2022-06-15	Band-Fastened, Convenience-Packaging for storing absorbent personal care articles
ZA201406369B (en)	2023-10-25	An iloperidone metabolite for use in the treatment of psychiatric disorders
EA201591155A1 (ru)	2016-01-29	Фармацевтическая композиция, содержащая n-[3-хлор-4-(3-фторбензилокси)фенил]-6-[5({[2-(метилсульфонил)этил]амино}метил)-2-фурил]хиназолин-4-амин или его фармацевтически приемлемые соль, сольват или сольватированную соль
HK1214511A1 (zh)	2016-07-29	鹽酸蘭地洛爾在快速性心律失常的長期治療中的用途
HK1193038A1 (zh)	2014-09-12	-甲氧基苯硫基 -甲基-丙基氨基- -二氫- -苯並巰氧雜卓用於治療癌症特別是用於預防和/或治療癌症轉移的用途
UA81330U (ru)	2013-06-25	Способ коррекции хроноритмов иммуноструктурного гомеостаза